MAIA Biotechnology, Inc. (MAIA)
1.33
-0.05
(-3.62%)
USD |
NYAM |
Aug 28, 16:00
1.325
0.00 (0.00%)
After-Hours: 20:00
MAIA Biotechnology Cash from Operations (Quarterly) : -6.750M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.750M |
| March 31, 2026 | -5.311M |
| December 31, 2025 | -7.020M |
| September 30, 2025 | -3.486M |
| June 30, 2025 | -4.135M |
| March 31, 2025 | -4.202M |
| December 31, 2024 | -3.908M |
| September 30, 2024 | -3.525M |
| June 30, 2024 | -4.685M |
| March 31, 2024 | -3.587M |
| December 31, 2023 | -3.992M |
| Date | Value |
|---|---|
| September 30, 2023 | -3.157M |
| June 30, 2023 | -2.561M |
| March 31, 2023 | -3.361M |
| December 31, 2022 | -2.509M |
| September 30, 2022 | -4.319M |
| June 30, 2022 | -2.282M |
| March 31, 2022 | -2.546M |
| December 31, 2021 | -1.607M |
| September 30, 2021 | -1.311M |
| June 30, 2021 | -0.951M |
| March 31, 2021 | -0.2533M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| TG Therapeutics, Inc. | 39.26M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | -0.065M |
| Free Cash Flow | -22.57M |
| Free Cash Flow Per Share (Quarterly) | -0.111 |
| Free Cash Flow to Equity (Quarterly) | -6.750M |
| Free Cash Flow to Firm (Quarterly) | -6.750M |
| Free Cash Flow Yield | -38.17% |